| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Mainstream news |
| Population | Men |
| Source | International Business Times UK |
| URL | ibtimes.co.uk/us-eases-testosterone-therapy-warnings-1807055 (opens in a new tab) |
Specific Claim Evaluated
The FDA has asked manufacturers to remove the age-related hypogonadism limitation and narrow the prostate cancer contraindication, citing TRAVERSE, which found no increase in major adverse cardiovascular events but a higher incidence of atrial fibrillation.
Primary Research Supporting or Contradicting the Claim
The FDA requested labeling updates in June 2026 (U.S. Food and Drug Administration, 2026b). TRAVERSE showed noninferiority for major adverse cardiac events with more atrial fibrillation, acute kidney injury and pulmonary embolism (Lincoff et al., 2023).
Corrected Evidence-Based Interpretation
The report is correct.
Rationale for Grade
Despite a sensational headline, the body describes the change as a request, summarizes TRAVERSE including its arrhythmia signal and notes the need for diagnosis and monitoring. No claim conflicts with the primary sources.
References
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events" - U.S. Food and Drug Administration. Testosterone information. Postmarket drug safety information for patients and providers. Updated June 2026.
Supporting excerpt: "FDA requested updates to testosterone prescribing information in June 2026"